

MEDICAL POLICY STATEMENT


Marketplace

Policy Name & Number

Date Effective


The

The MEDICAL Policy Statement detailed above



- b. patient is a candidate for transplant following bridge therapy by radiofrequency ablation
 - c. patient is not a surgical candidate (or elects against surgery)
 - d. patient is not a transplant candidate
3. tumor has all the following:
- a. location amenable to percutaneous, minimally invasive or open surgical ablation
 - b. margins accessible to ablation
 - c. not in close proximity to critical structures (eg, major vessels, major bile ducts, diaphragm, other intra-abdominal

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.



14. Wang N, Xu J, Wang G, et al. Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure. *Thorac Cancer*. 2022; 13(18):2557-2565. doi:10.1111/1759-7714.14589
15. Wu X, Uhlig J, Blasberg JD, et al. Microwave ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: a cost-effectiveness analysis. *J Vasc Interv Radiol*. 2022;33(8):964-971.e2. doi:10.1016/j.jvir.2022.04.019

Independent medical review September 2022

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.